copyright 1 MG-SEMAGLUTIDE for Dummies
The demo obtained each its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and excellent improvements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH as compared to placebo.1Specific Populations Determine